These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 21396745)
1. Preparation and evaluation of tetrabenazine enantiomers and all eight stereoisomers of dihydrotetrabenazine as VMAT2 inhibitors. Yao Z; Wei X; Wu X; Katz JL; Kopajtic T; Greig NH; Sun H Eur J Med Chem; 2011 May; 46(5):1841-8. PubMed ID: 21396745 [TBL] [Abstract][Full Text] [Related]
2. 9-Cyclopropylmethoxy-dihydrotetrabenazine and its stereoisomers as vesicular monoamine transporter-2 inhibitors. Wang W; Lin S; Du G; Bai X; Lu J; Ye L; Wang H; Zhang R; Tian J Future Med Chem; 2022 Jul; 14(13):991-1003. PubMed ID: 35638444 [No Abstract] [Full Text] [Related]
3. Synthesis and evaluation of 2-amino-dihydrotetrabenzine derivatives as probes for imaging vesicular monoamine transporter-2. Zhu L; Liu J; Kung HF Bioorg Med Chem Lett; 2009 Sep; 19(17):5026-8. PubMed ID: 19632829 [TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of 3-alkyl-dihydrotetrabenazine derivatives as vesicular monoamine transporter-2 (VMAT2) ligands. Zheng P; Lieberman BP; Choi SR; Plöessl K; Kung HF Bioorg Med Chem Lett; 2011 Jun; 21(11):3435-8. PubMed ID: 21531556 [TBL] [Abstract][Full Text] [Related]
5. VMAT2 inhibitors for the treatment of hyperkinetic movement disorders. Koch J; Shi WX; Dashtipour K Pharmacol Ther; 2020 Aug; 212():107580. PubMed ID: 32454050 [TBL] [Abstract][Full Text] [Related]
6. Synthesis and analysis of dihydrotetrabenazine derivatives as novel vesicular monoamine transporter 2 inhibitors. Yang Y; Yu D; Zhu X; Du G; Wang W; Zou F; Wang H; Zhang R; Ye L; Tian J Eur J Med Chem; 2021 Nov; 224():113718. PubMed ID: 34329999 [TBL] [Abstract][Full Text] [Related]
7. Deutetrabenazine for the treatment of Huntington's chorea. Bashir H; Jankovic J Expert Rev Neurother; 2018 Aug; 18(8):625-631. PubMed ID: 29996061 [TBL] [Abstract][Full Text] [Related]
8. Binding of alpha-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific. Kilbourn M; Lee L; Vander Borght T; Jewett D; Frey K Eur J Pharmacol; 1995 May; 278(3):249-52. PubMed ID: 7589162 [TBL] [Abstract][Full Text] [Related]
9. Pyrrolidine analogs of GZ-793A: synthesis and evaluation as inhibitors of the vesicular monoamine transporter-2 (VMAT2). Penthala NR; Ponugoti PR; Nickell JR; Deaciuc AG; Dwoskin LP; Crooks PA Bioorg Med Chem Lett; 2013 Jun; 23(11):3342-5. PubMed ID: 23597792 [TBL] [Abstract][Full Text] [Related]
10. Absolute configuration of (+)-alpha-dihydrotetrabenazine, an active metabolite of tetrabenazine. Kilbourn MR; Lee LC; Heeg MJ; Jewett DM Chirality; 1997; 9(1):59-62. PubMed ID: 9094204 [TBL] [Abstract][Full Text] [Related]
14. Identification of conformationally sensitive residues essential for inhibition of vesicular monoamine transport by the noncompetitive inhibitor tetrabenazine. Ugolev Y; Segal T; Yaffe D; Gros Y; Schuldiner S J Biol Chem; 2013 Nov; 288(45):32160-32171. PubMed ID: 24062308 [TBL] [Abstract][Full Text] [Related]
15. Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters. Goswami R; Ponde DE; Kung MP; Hou C; Kilbourn MR; Kung HF Nucl Med Biol; 2006 Aug; 33(6):685-94. PubMed ID: 16934687 [TBL] [Abstract][Full Text] [Related]
16. (+)-9-Benzyloxy-α-dihydrotetrabenazine as an important intermediate for the VMAT2 imaging agents: absolute configuration and chiral recognition. Liu C; Chen Z; Li X; Tang J; Qin X Chirality; 2013 Apr; 25(4):215-23. PubMed ID: 23532997 [TBL] [Abstract][Full Text] [Related]
17. A concise total synthesis of (+)-tetrabenazine and (+)-α-dihydrotetrabenazine. Paek SM; Kim NJ; Shin D; Jung JK; Jung JW; Chang DJ; Moon H; Suh YG Chemistry; 2010 Apr; 16(15):4623-8. PubMed ID: 20235241 [TBL] [Abstract][Full Text] [Related]